Trident Texofab Limited (BOM:540726)

Trident Texofab Revenue

In the fiscal year ending March 31, 2026, Trident Texofab had annual revenue of 1.20B INR, down -1.80%. Trident Texofab had revenue of 341.03M in the quarter ending March 31, 2026, a decrease of -10.74%.

• Revenue: 1.20B
• Revenue Growth: -1.80%
• P/S Ratio: 0.52
• Revenue / Employee: 19.03M
• Employees: 63
• Market Cap: 625.32M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	1.20B	-21.93M	-1.80%
Mar 31, 2025	1.22B	225.73M	22.69%
Mar 31, 2024	994.84M	31.27M	3.25%
Mar 31, 2023	963.56M	120.63M	14.31%
Mar 31, 2022	842.93M	343.67M	68.83%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 2, 2026

Data Sources Report a data error